
|Articles|April 24, 2022
Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3
Author(s)David Hutton
David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Coave Therapeutics reveals lead gene therapy program, CoTx-10
2
Harrow completes acquisiton of Melt Pharmaceuticals
3
Foundation Fighting Blindness releases 4-year RUSH2A data to public
4
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1
5


















































.png)


